Navigation Links
Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
Date:11/17/2010

DALLAS and NEW YORK, Nov. 17, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.  The poster being displayed, entitled "Vitamin B-12 Nanoparticles for the Targeted Delivery of RNAi Therapeutics", summarizes key findings of the Company's rebranded Cobalamin program, CobaCyte for RNAi.  The second poster, entitled "Preclinical and Clinical Studies of ProLindac: A Novel Polymer Prodrug of DACH Platinum", details the distinct attributes and advantages of utilizing Access' second generation DACH Platinum, ProLindac.

"We are pleased to be included in this year's Innovations in Cancer Prevention and Research Conference as the team's research in both programs support a significant opportunity in treating various cancers," said David Nowotnik, Senior VP of Research and Development, Access Pharmaceuticals, Inc.  He continued, "Given the recently commenced combination trial for ProLindac and the heightened interest surrounding our CobaCyte program, this conference, with its astute multidisciplinary audience, is an ideal venue to display the work currently under development at Access."

The conference is organized by the Cancer Prevention and Research Institute of Texas (CPRIT).

For information on the conference, please visit: http://cpritconference2010.eventbrite.com/

Access Pharmaceuticals recently received $1.5 million in government grants under the Qualifying Therapeutic Discovery Project (QTDP).  The Company's ProLindac and CobaCyte programs each received
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
2. Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th
3. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
4. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
5. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
6. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
7. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
8. Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases
9. The Development of Medical Foundations in the San Diego Area will Restrict Physician Access for Pharmaceutical Reps
10. Recent Patient Series Demonstrates Spirus Medicals Power Spiral Endoscope Enables Unprecedented Access to GI Tract
11. Utahs Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Three Independent Clinical Trials Initiated with Teplizumab Manufactured at ... ... that its Protege trial is actively enrolling adults and children ages,8 to ... evaluate the safety and efficacy of three teplizumab dosing,regimens administered at the ...
... versus 26.2 for ... Vidaza compared to ... conventional ... modifier to show survival benefit in cancer Stratified log-rank p-value = 0.0001, Hazard ...
Cached Medicine Technology:MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 2MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 3MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 2Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 3Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 5Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 6Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 7Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 8
(Date:7/9/2014)... common type of lung cancer, researchers have uncovered mutations ... forming tumors. The new knowledge may expand treatments for ... already are available or are in clinical trials. , ... The Cancer Genome Atlas (TCGA), including researchers at Washington ... School and other institutions, studied tumors from 230 patients ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2
... to debate on the supplement but doesn,t settle it, one ... Glucosamine sulfate, a popular dietary supplement purported to ease the ... people with arthritis in their hips. , That,s the conclusion ... a placebo for the treatment of mild to moderate hip ...
... named the,fastest growing PR agency in the U.S., announced ... Symposium," showcasing exclusive consumer,brands from 5W,s Health & Beauty ... April 22nd from 10 a.m. to 2 p.m. at ... Hearst building and near the Time,Warner Center., This ...
... to Industry Best-Practices, MINNEAPOLIS, Feb. ... established national healthcare consulting practice, has ... which a PBM or Health,Plan can ... core organizational quality, customer service, communications ...
... Radiology Group (FRG),and the Brownsville Tri-County Hospital have ... Brownsville,s exclusive provider of,diagnostic imaging services., "The ... work,with," stated Richard W. Hritz, CEO of the ... involvement in working to bring this,hospital back online, ...
... 18 In rural Milledgeville,Georgia, 62 year old insulin-dependent ... 10,000+ mile perimeter walk of the United,States raising awareness ... "I,ve hit milestones in San Diego, Seattle, Chicago, Boston, ... of diabetes, only,fewer resources to manage it. We can ...
... Feb. 18 Be aware, be,prepared and take ... State University trauma expert on,preventing tragedies like the ... Briana Nelson Goff, associate dean of K-State,s College ... and human services,leads the Trauma Research, Education and ...
Cached Medicine News:Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 2Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 3Health News:5W Public Relations Hosts Exclusive Beauty & Wellness Industry Event 2Health News:Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 3Health News:Mr. Diabetes(R) Hits 9,000 Mile Mark of 10,000+ Mile Walk to Raise Awareness About Diabetes 2Health News:K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: